# Human Tissues, Lipidomics, and Proteomics Core

> **NIH NIH P01** · NEW YORK UNIVERSITY D/B/A NYU LONG ISLAND SCHOOL OF MEDICINE · 2024 · $220,739

## Abstract

SUMMARY – HUMAN TISSUES, LIPOPROTEINS, LIPIDOMICS, & PROTEOMICS CORE (C2)
The Human Tissues, Lipoproteins, Lipidomics, and Proteomics Core (Core 2, C2) will focus on
providing human tissues and analytical capabilities to all three projects to enhance translatability
of mouse studies proposed in P1–P3 to clinical practice in humans. In parallel, Core 2 will
provide lipoprotein, lipidomic, and proteomic analyses currently not provided by our institutional
Metabolomics Core. The cardiovascular research community has shown many important
correlations between clinical outcomes and the plasma levels of atherogenic particles of
different densities, as determined by ultracentrifugation. More detailed analyses are now
uncovering additional risk for cardiovascular disease (CVD) within these particles, such as the
content of apoC3 and ceramides. For this PPG, Core 2 will provide a more granular analysis of
lipoproteins isolated by centrifugation and size exclusion chromatography through both directed
and unbiased lipidomic and proteomic analyses of these particles. In addition, clinical samples
(sera, liver, adipose) obtained by the core director will be provided to investigators in all three
projects. These services will avoid the need for PPG investigators to maintain the required
instrumentation in their own laboratories or use expensive commercial services. By centralizing
and standardizing procedures, Core 2 provides a common set of analytical tools to provide a
unified understanding of molecular mechanisms involved in pathophysiologic processes of
atherosclerosis, macrophage biology, regulation of triglyceride-rich lipoproteins, and obesity. By
complementing and integrating with the service provided by Core 1, Core 2 staff also provide
bioinformatics support to analyze and interpret proteomic and lipidomic data sets, making Core
2 capabilities available to PPG investigators with little background or expertise in these
analytical technologies. A key long-term goal is to integrate quantitative analyses of lipidomic
data with functional studies to provide a systems biology view of diabetes-related cardiovascular
disease. Core 2 will also develop new analytical methods tailored to specific research objectives
of PPG investigators. Specifically, we will obtain and use standards to quantify and discover
candidate lipids whose role in atherosclerosis is being investigated. These methods will be
extensively used by PPG investigators. Core 2 will offer these services with optimal efficiency
and cost-effectiveness, avoiding the need for individuals to pursue such analyses outside the
PPG.

## Key facts

- **NIH application ID:** 10834202
- **Project number:** 5P01HL160470-02
- **Recipient organization:** NEW YORK UNIVERSITY D/B/A NYU LONG ISLAND SCHOOL OF MEDICINE
- **Principal Investigator:** Jose Orlando Aleman
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $220,739
- **Award type:** 5
- **Project period:** 2023-05-01 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10834202

## Citation

> US National Institutes of Health, RePORTER application 10834202, Human Tissues, Lipidomics, and Proteomics Core (5P01HL160470-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10834202. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*